W H Sherman

Summary

Affiliation: Columbia University
Country: USA

Publications

  1. ncbi Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma
    Howard L Kaufman
    Tumor Immunology Laboratory, Division of Surgical Oncology, Columbia University, New York, NY, USA
    J Transl Med 7:2. 2009
  2. ncbi Combination gemcitabine and docetaxel therapy in advanced adenocarcinoma of the pancreas
    W H Sherman
    Division of Medical Oncology, Department of Medicine, New York Presbyterian Hospital, Columbia University College of Physicians and Surgeons, New York, NY, USA
    Oncology 60:316-21. 2001
  3. ncbi Sirolimus can reverse resistance to gemcitabine, capecitabine and docetaxel combination therapy in pancreatic cancer
    William H Sherman
    Columbia University, College Physicians and Surgeons, New York, NY, USA
    JOP 10:393-5. 2009

Collaborators

  • Howard L Kaufman
  • Bret Taback
  • Dae Won Kim
  • William H Shingler
  • Stuart Naylor
  • Josephine Mitcham
  • Seunghee Kim-Schulze
  • Dorota Moroziewicz
  • Gail DeRaffele
  • Miles W Carroll
  • Richard Harrop

Detail Information

Publications3

  1. ncbi Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma
    Howard L Kaufman
    Tumor Immunology Laboratory, Division of Surgical Oncology, Columbia University, New York, NY, USA
    J Transl Med 7:2. 2009
    ..A modified vaccinia virus Ankara (MVA) encoding 5T4 was tested in combination with high-dose IL-2 to determine the safety, objective response rate and effect on humoral and cell-mediated immunity...
  2. ncbi Combination gemcitabine and docetaxel therapy in advanced adenocarcinoma of the pancreas
    W H Sherman
    Division of Medical Oncology, Department of Medicine, New York Presbyterian Hospital, Columbia University College of Physicians and Surgeons, New York, NY, USA
    Oncology 60:316-21. 2001
    ..To determine the clinical and laboratory response rate of a gemcitabine and docetaxel combination in human adenocarcinoma of the pancreas in vitro and in vivo...
  3. ncbi Sirolimus can reverse resistance to gemcitabine, capecitabine and docetaxel combination therapy in pancreatic cancer
    William H Sherman
    Columbia University, College Physicians and Surgeons, New York, NY, USA
    JOP 10:393-5. 2009
    ..If resistance can be reversed or prevented, the chemotherapeutic benefit may be prolonged...